Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

Cancer ◽  
2009 ◽  
Vol 115 (9) ◽  
pp. 1867-1874 ◽  
Author(s):  
Lois M. Ramondetta ◽  
Alaina J. Johnson ◽  
Charlotte C. Sun ◽  
Neely Atkinson ◽  
Judith A. Smith ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Endometrioid Adenocarcinoma ◽  
Phase 2 ◽  
Ru 486 ◽  
Phase 2 Trial ◽  
Stromal Sarcoma

Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5595-5595
Author(s):  
T. W. Burke ◽  
M. A. Navo ◽  
J. A. Smith ◽  
M. S. Jung ◽  
R. Broaddus ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adverse Events ◽  
Phase Ii ◽  
Stable Disease ◽  
Single Agent ◽  
Female Genital Tract ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Endometrioid Adenocarcinoma ◽  
Stromal Sarcoma

5595 Background: Endometrial cancer is the most common cancer of the female genital tract. It affected 41,200 women in the year 2006 and caused 7,350 deaths. Therapy options for recurrent/advanced endometrial cancer are limited. Treatment with radiation and chemotherapy has shown only limited success. Methods: In a phase II IRB approved trial, Mifepristone was given to patients with progesterone receptor positive advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma at a dose of 200mg/day orally. Patients were evaluated every 4 weeks to assess treatment-related toxicities and response. Imaging was obtained initially at 8 weeks then every 12 weeks for evaluation of response. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to assess toxicity. Results: Twelve of 13 enrolled patients were evaluable for response in the first phase of accrual. Stable disease was noted in 3/12 (16, 20, and 44+ weeks). Two were endometrioid endometrial cancer and one with LGESS. No complete responses were seen, one patient remains in treatment. The most frequently reported grade 1–2 tumor related toxicities were anorexia, mood alterations, and fatigue (55%). Twenty-seven percent had asymptomatic elevations of ACTH. The most common Grade 3 toxicities were fatigue and dyspnea (27% and 18%). Only one patient experienced a Grade 4 dyspnea. No serious treatment-related adverse events occurred. Conclusions: Single agent mifepristone in patients with recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma showed no complete responses. Stable disease was reported 25%, one patient remains stable at 44 weeks. Recent reports suggests that mifepristone may also work via non hormonal targets while single agent mifepristone has minimal activity in this setting. Further evaluation in combination therapy in endometrial cancer should be considered. No significant financial relationships to disclose.

scholarly journals CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report

2021 ◽  
Vol 16 (9) ◽  
pp. 2774-2779
Author(s):  
Satoshi Suzuki ◽  
Ryo Kurokawa ◽  
Tetsushi Tsuruga ◽  
Mayuyo Mori‑Uchino ◽  
Haruka Nishida ◽  
...  
Keyword(s):  
Case Report ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Imaging Findings ◽  
Stromal Sarcoma

Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer

2012 ◽  
Vol 39 (1) ◽  
pp. 424-429 ◽  
Author(s):  
Tomoko Kashiyama ◽  
Katsutoshi Oda ◽  
Kei Kawana ◽  
Takahide Arimoto ◽  
Yukiko Kanetaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Woman ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

Low-Grade Endometrial Stromal Sarcoma with Florid Intravenous Component

2008 ◽  
Vol 66 (1) ◽  
pp. 8-11 ◽  
Author(s):  
Keith Wing-Kit Lo ◽  
Mei-Yung Yu ◽  
Tak-Hong Cheung
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

scholarly journals 82 Unusual extrauterine localisation of low grade endometrial stromal sarcoma : report of two cases

2020 ◽  
Author(s):  
M Slimene ◽  
I Bouraoui ◽  
M Bouhani ◽  
S Sakhri ◽  
N Boujelbene ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

Severe Abdominal Recurrence of Low-grade Endometrial Stromal Sarcoma After Hysteroscopic Surgery

2021 ◽  
Vol 41 (8) ◽  
pp. 4013-4016
Author(s):  
DAISUKE TAMURA ◽  
DAICHI MAEDA ◽  
KATSUHIKO ENOMOTO ◽  
HIROKAZU SATO
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Hysteroscopic Surgery ◽  
Stromal Sarcoma

scholarly journals Primary low-grade endometrial stromal sarcoma of the omentum

2017 ◽  
Vol 21 ◽  
pp. 119-121 ◽  
Author(s):  
Kiran Clair ◽  
Juliet Wolford ◽  
Sonia Veran-Taguibao ◽  
Grace Kim ◽  
Ramez N. Eskander
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

scholarly journals Low-Grade Endometrial Stromal Sarcoma in a 22-Year-Old Maiden Female: A Rare Case Report from Syria

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Lana Nseir ◽  
Georget Mansour ◽  
Junior Makhoul ◽  
Luna Skaf ◽  
Mohammad Ziad Dahhan ◽  
...  
Keyword(s):  
Case Report ◽  
Rare Case ◽  
Treatment Plan ◽  
Endometrial Stromal Sarcoma ◽  
Abnormal Uterine Bleeding ◽  
Low Grade ◽  
Stromal Sarcoma ◽  
Rapid Enlargement ◽  
Rare Case Report ◽  
Immunohistochemical Studies

Endometrial stromal sarcoma (ESS) is a rare and challenging type of endometrial tumor, constituting only about 0.2% of all uterine malignancies and occurring in women 42–58 years of age. ESS is usually misdiagnosed as leiomyoma. They both have nonspecific symptoms, which makes the diagnosis of ESS difficult to achieve. As the ESS is infrequently encountered, optimal management is quite debatable. Here, we report a rare case of a 22-year-old Syrian female who presented with abnormal uterine bleeding; the preoperative diagnosis suggested leiomyoma while histopathological and immunohistochemical studies confirmed the diagnosis of LG-ESS stage IIA. Therefore, the treatment plan was shifted from a conservative myomectomy to a total hysterectomy with both adnexa. The aim of this case report is to draw attention to this uncommon tumor at young age of patients as well as to have awareness of the necessity to suspect this diagnosis especially with the presentation of rapid enlargement of uterine leiomyoma.

Sign in / Sign up

Export Citation Format

Share Document